Introduction/objectives The effect of intravenous (IV) golimumab on health-related quality of
life (HRQoL) and productivity in patients with ankylosing spondylitis (AS) was evaluated.
Method Patients were randomized to IV golimumab 2 mg/kg (n= 105) at weeks 0, 4, then
every 8 weeks (q8w) through week 52 or placebo (n= 103) at weeks 0, 4, 12, with crossover
to golimumab 2 mg/kg at weeks 16, 20, then q8w through week 52. Changes from baseline
in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily …

Introduction/objectives To evaluate changes in health-related quality of life (HRQoL) and
productivity following treatment with intravenous (IV) golimumab in patients with psoriatic
arthritis (PsA). Methods Patients were randomized to IV golimumab 2 mg/kg (n= 241) at
Weeks 0, 4, then every 8 weeks (q8w) through Week 52 or placebo (n= 239) at Weeks 0, 4,
then q8w, with crossover to IV golimumab 2 mg/kg at Weeks 24, 28, then q8w through Week
52. Change from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual …